Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback